Pil S. Sung

St. Vincent's Hospital
Suwon, Republic of Korea

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 181 publications

Comparison of Second-line Hepatic Arterial Infusion Chemotherapy and Tyrosine Kinase Inhibitors in Advanced Hepatocellular Carcinoma.

Comparison of Second-line Hepatic Arterial Infusion Chemotherapy and Tyrosine Kinase Inhibitors in Advanced Hepatocellular Carcinoma.

Journal: Radiology
Published: August 04, 2026

Emerging Indices Outperform Traditional Fibrosis Scores in Young Metabolic Dysfunction-Associated Steatotic Liver Disease Across Divergent Screening Goals.

Emerging Indices Outperform Traditional Fibrosis Scores in Young Metabolic Dysfunction-Associated Steatotic Liver Disease Across Divergent Screening Goals.

Journal: Journal of gastroenterology and hepatology
Published: June 02, 2026

Oral Health-Related Quality of Life and Social Engagement: Gender Differences.

Oral Health-Related Quality of Life and Social Engagement: Gender Differences.

Journal: Journal of dental research
Published: May 06, 2026

Toward a future role for liver biopsy in HCC: literature evidence and survey-based perspectives from Korean experts.

Toward a future role for liver biopsy in HCC: literature evidence and survey-based perspectives from Korean experts.

Journal: Journal of liver cancer
Published: May 04, 2026

Regorafenib as Second-Line Versus Later-Line Therapy in Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study with Exploratory Analysis of Prior Immune Checkpoint Inhibitor Exposure.

Regorafenib as Second-Line Versus Later-Line Therapy in Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study with Exploratory Analysis of Prior Immune Checkpoint Inhibitor Exposure.

Journal: Targeted oncology
Published: April 18, 2026

Blocking the gut-liver IgA axis attenuates macrophage-mediated inflammation and injury in alcohol-associated liver disease.

Blocking the gut-liver IgA axis attenuates macrophage-mediated inflammation and injury in alcohol-associated liver disease.

Journal: Gut
Published: March 09, 2026

Shelterin Component TPP1 Drives Tumor Progression and Predicts Poor Prognosis in Hepatocellular Carcinoma.

Shelterin Component TPP1 Drives Tumor Progression and Predicts Poor Prognosis in Hepatocellular Carcinoma.

Journal: Biomedicines
Published: December 30, 2025

Incidence and risk stratification of hepatitis B reactivation in patients receiving anti-CD38 monoclonal antibody therapy.

Incidence and risk stratification of hepatitis B reactivation in patients receiving anti-CD38 monoclonal antibody therapy.

Journal: Journal of hepatology
Published: December 09, 2025

Prognostic Significance of Glypican-3 Expression in Hepatocellular Carcinoma Treated with Atezolizumab-Bevacizumab.

Prognostic Significance of Glypican-3 Expression in Hepatocellular Carcinoma Treated with Atezolizumab-Bevacizumab.

Journal: Cancers
Published: November 16, 2025

Fibroblast- and Macrophage-Derived Thrombospondin-1 Orchestrates the Fibroinflammatory Niche in Metabolic Dysfunction-Associated Steatohepatitis-Induced Fibrosis.

Fibroblast- and Macrophage-Derived Thrombospondin-1 Orchestrates the Fibroinflammatory Niche in Metabolic Dysfunction-Associated Steatohepatitis-Induced Fibrosis.

Journal: Diabetes & metabolism journal
Published: November 13, 2025

Machine learning based hepatic safety score predicts decompensation in hepatocellular carcinoma systemic therapy.

Machine learning based hepatic safety score predicts decompensation in hepatocellular carcinoma systemic therapy.

Journal: NPJ digital medicine
Published: October 25, 2025

Low Tumor Burden Predicts Benefit from Transarterial Treatment in Hepatocellular Carcinoma with Extrahepatic Metastasis: A Nationwide Cohort Study.

Low Tumor Burden Predicts Benefit from Transarterial Treatment in Hepatocellular Carcinoma with Extrahepatic Metastasis: A Nationwide Cohort Study.

Journal: Liver cancer
Published: October 22, 2025
Showing 1-12 of 181

Last Updated: 09/26/2026